6 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 17%
A multi-day slide in the biotech’s stock prompts a closer look at the numbers behind the negative momentum.
A six-day slide in Arrowhead Pharmaceuticals (ARWR) stock has erased about $2.2 billion from its market value. The stock has now moved lower for 6 consecutive trading days, a cumulative loss of 17.4%.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
ARWR Versus The S&P 500, Streak And Beyond
Here is how ARWR stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | ARWR | S&P 500 |
|---|---|---|
| 1D | -0.1% | 0.4% |
| 6D (Current Streak) | -17.4% | 0.9% |
| 1M (21D) | -3.6% | 1.9% |
| 3M (63D) | 7.7% | 8.7% |
| YTD 2026 | 8.2% | 10.6% |
| 2025 | 253.1% | 16.4% |
| 2024 | -38.6% | 23.3% |
| 2023 | -24.6% | 24.2% |
The selling streak aligns with strained profitability metrics.
This decline is specific to the company; over the same 6 trading days, the S&P 500 returned +0.9%. While the company’s 3-year average annual revenue growth is 454.7%, its profitability metrics show significant pressure.
Operating margin over the last twelve months is -35.7%, against an S&P 500 median of 18.4%. Such streaks are not unusual in the current market, with 34 S&P 500 stocks on losing streaks of 3 days or more.
A streak is a signal to re-evaluate, not a command to act.
A persistent move is information. It signals that the market’s attention is focused and momentum has taken hold, but it is not an instruction to buy or sell. The disciplined response is to check the business fundamentals against the stock’s new price.
The data shows a company with significant long-term returns of +285.9% over the trailing twelve months, now facing a period of negative sentiment. This allows an investor to begin assessing whether the recent price action reflects a change in the underlying story or a shorter-term shift in focus.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
And for anyone who would rather own the whole group than one company’s story, a biotech ETF like XBI gives you broad exposure. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.